Pulmonary Arterial Hypertension Market By Drug Class ( Prostacyclin and Prostacyclin Analogs, Endothelin Receptor Antagonists (ERAs), Phosphodiesterase 5 (PDE-5) Inhibitors & Soluble Guanylate Cyclase (sGC) Stimulators ), By Application ( Hospitals & Clinics ), Industry Trends, Estimation & Forecast, 2017-2025

March 2018

 Pages: 180

 ERC 5740


Pulmonary Arterial Hypertension Market is expected to grow with a CAGR of xx% during the forecast period of 2018 to 2025.

Pulmonary arterial hypertension, also called as (PAH) is a type of a broader condition known as pulmonary hypertension. In this rare condition, a high blood pressure is generated in the lung as a result of increased pressure in the vessels caused by hindrance in the small arteries, which are present the lung. The main cause of pulmonary arterial hypertension is usually unknown, but people encountering issues such as illegal drug use, liver disorders, blood clots in lungs, and congestive heart failure are found more prone to PAH. Moreover, factors such as increasing consumption of unhealthy and junk food, sedentary lifestyle, and growing number of cardiac patients are expected to stimulate the market growth. In addition to this, continuous favorable initiatives taken by government for spreading awareness regarding the treatment of pulmonary arterial hypertension, coupled with provision of funds for the research and development of PAH related drugs is expected to give a push to the market. However, being a rare condition, the relatively small presence of target population might act as a restraining factor for the market growth.
The report provides detailed qualitative and quantitative analysis of the pulmonary arterial hypertension Market. Market size and forecast in terms of value has been provided for the period - (2018 - 2025), for the segments namely drug class, and geography.

Pulmonary Arterial Hypertension Market Player Analysis -

The report presents detailed analysis of major players operating in pulmonary arterial hypertension market. Few of the include Bayer HealthCare, Actelion Pharmaceuticals, Ltd., GlaxoSmithKline plc, Novartis International AG, Gilead Sciences, Inc., United Therapeutics Corporation, and Pfizer, Inc. Detailed coverage on these market players with information on their revenue from pulmonary arterial hypertension business, market share, gross margin and their growth strategies have been provided in the report.

Pulmonary Arterial Hypertension Market Segmentation

Pulmonary arterial hypertension market is segmented on the basis of drug class, application and geography. By type, the market is segmented into prostacyclin and prostacyclin analogs, endothelin receptor antagonists (ERAs), phosphodiesterase 5 (PDE-5) inhibitors and soluble guanylate cyclase (sGC) stimulators. On the basis of application, the market is categorized as hospitals, clinics and others. Geographically, the market is categorized into North America, Europe, Asia Pacific and Rest of the World.

Pulmonary Arterial Hypertension Market Segmentation

By Drug Class
   • Prostacyclin and Prostacyclin Analogs
   • Endothelin Receptor Antagonists (ERAs)
   • Phosphodiesterase 5 (PDE-5) Inhibitors
   • Soluble Guanylate Cyclase (sGC) Stimulators

By Application
   • Hospitals
   • Clinics
   • Others

Pulmonary Arterial Hypertension Market By Geography
   • North America
           o U.S.
           o Canada
           o Mexico
   • Europe
           o UK
           o Germany
           o France
           o Russia
           o Rest of Europe
   • Asia Pacific
           o China
           o Japan
           o India
           o Rest of APAC
   • Rest of the world
           o Latin America
           o Middle East
           o Africa

Pulmonary Arterial Hypertension Market Key Players

• Bayer HealthCare
• Actelion Pharmaceuticals, Ltd.
• Novartis International AG
• Gilead Sciences, Inc.
• GlaxoSmithKline plc
• United Therapeutics Corporation
• Pfizer, Inc.

Please fill in the form below to Request for Customized Report
Your personal details are safe and secured with us. Privacy Policy

To request sample copy of this report, please complete the form below verified and secure

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report. This also includes a 30 minute free analyst discussion post report purchase.

Your personal details are safe and secured with us. Privacy Policy

    What Information does this report contain?

    • What was the market size of the pulmonary arterial hypertension market in 2017 and the expected market size by 2025, along with the growth rate?
    • An in-depth analysis of the current impacting factors, opportunities and challenges/restraints in the market
    • Which are the largest revenue generating products, services or regions, and their comparative growth rate?
    • Which technology is in trend and how would it evolve during the forecast period (2017 - 2025)?
    • Which are the leading companies in the pulmonary arterial hypertension market and their competitive positioning basis their market share, product portfolio, strategic attempts and business focus?

Purchase Options

Offers & Discounts

  • Chapter purchase
  • Historical market data
  • Country level data breakdown
  • Free customization*
  • Discounts for first time
  • Special pricing for
              non-business entities


  • We offer 20% free customization on every purchase.

Get in touch!